Gut hormone leads to weight loss in overweight or obese patients

January 10, 2012, British Medical Journal

Giving overweight or obese patients a gut hormone that suppresses appetite leads to clinically beneficial weight loss as well as reduced blood pressure and cholesterol levels, finds a study published in the British Medical Journal today.

Glucagon-like peptide-1 (GLP-1) is a hormone that is secreted from the intestine when we eat. GLP-1 based therapy was recently introduced as a new treatment for patients with because of its ability to regulate .

But it also suppresses food intake and appetite, making it an interesting approach in the treatment of obesity.

So researchers at the University of Copenhagen set out to determine the effect of glucagon-like peptide-1 receptor (GLP-1R) on weight loss. They also looked at their effect on blood pressure, cholesterol and liver enzyme levels, and blood sugar (glycaemic) control.

They analysed the results of 25 involving over 6,000 patients. Differences in study design and quality were taken into account to minimise bias.

They found that patients who received clinically relevant doses of GLP-1R agonists for at least 20 weeks achieved a greater weight loss compared with the control groups.

The benefit was seen for patients with and without type 2 diabetes, but may be more pronounced in patients without diabetes.

GLP-1R agonists also had beneficial effects on blood pressure, cholesterol and improved glycaemic control in patients with type 2 diabetes. There was no statistically significant effect on .

Common side effects included nausea, vomiting and diarrhoea, but did not seem to affect the number of patients dropping out of the trials, suggesting that overall with the treatment is relatively high.

The authors say that their analysis "provides convincing evidence that GLP-1R agonists, when given to obese patients with or without diabetes, result in clinically relevant beneficial effects on body weight. Additional beneficial effects on blood pressure and total cholesterol might also be achieved."

They believe that the intervention "should be considered in patients with diabetes who are obese or overweight" and call for further studies "to elucidate the effects of GLP-1R agonists in the treatment of obese patients without diabetes."

While these results highlight the weight-reducing benefits of GLP-1 agonists, they should not alter current practice, says Professor Raj Padwal from the University of Alberta in an accompanying editorial. He argues that "modification of diet and lifestyle remains the cornerstone of the treatment of type 2 diabetes."

He also points out that the safety of GLP-1 agonists is still unknown and says "continued and close surveillance of these new agents using all available data sources is warranted."

Explore further: Research reveals hormone action that could lead to treatments for type 2 diabetes

Related Stories

Research reveals hormone action that could lead to treatments for type 2 diabetes

September 30, 2011
(Medical Xpress) -- Researchers at the University of Cincinnati have discovered that the immediate improvement in blood sugar (blood glucose) for those with type 2 diabetes who undergo gastric bypass surgery is related to ...

Improving psoriasis with GLP-1 analogue therapy

December 13, 2011
(Medical Xpress) -- UCD clinician scientists and researchers from NUI Maynooth and Trinity College led by Conway Fellow, Professor Donal O’Shea have reported an improvement in the severity of psoriasis in patients following ...

Scientists reassess weight loss surgery for type 2 diabetes

January 4, 2012
Weight loss surgery is not a cure for type 2 diabetes, but it can improve blood sugar control, according to a new study published in the British Journal of Surgery. Whereas some previous studies have claimed that up to 80 ...

Recommended for you

Bariatric surgery prolongs lifespan in obese

January 16, 2018
Obese, middle-age men and women who had bariatric surgery have half the death rate of those who had traditional medical treatment over a 10-year period, reports a study that answers questions about the long-term risk of the ...

Evening hours may pose higher risk for overeating, especially when under stress, study finds

January 16, 2018
Experiments with a small group of overweight men and women have added to evidence that "hunger hormone" levels rise and "satiety (or fullness) hormone" levels decrease in the evening. The findings also suggest that stress ...

Sugar-sweetened drinks linked to overweight and obesity in children, adults: Analysis of new studies

December 23, 2017
A new review of the latest evidence on sugar-sweetened beverages (SSBs)- which includes 30 new studies published between 2013 and 2015 (and none of them industry sponsored) - concludes that SSB consumption is associated with ...

As income rises, women get slimmer—but not men

December 21, 2017
(HealthDay)—A comprehensive survey on the widening American waistline finds that as paychecks get bigger, women's average weight tends to drop.

Policy and early intervention can curb obesity rates

December 18, 2017
More information and emphasis on dietary lifestyle changes that prevent obesity, and its comorbidities, have not reduced the rise in obesity in U.S. adults and adolescents, according to a recent study in the New England Journal ...

Warning labels can help reduce soda consumption and obesity, new study suggests

December 15, 2017
Labels that warn people about the risks of drinking soda and other sugar-sweetened beverages can lower obesity and overweight prevalence, suggests a new Johns Hopkins Bloomberg School of Public Health study.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Hospital Management
not rated yet Jan 10, 2012
If there is Overweight problem due to medical complications then how to loss weight..

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.